文献速递艾滋病与性传播感染新发突发、热带与寄生虫病医院感染防控

HIV感染者中的猴痘:多中心队列中诊断预测因素、结局与疫苗有效性

Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort.
PubMed 文献 · Clin Infect Dis · 2026-01-01

在美国9个艾滋病研究中心网络站点纳入2022年1月1日后有初级保健就诊的19777名HIV感染者,识别413例猴痘病例(2.2例/100人年)。未抗逆转录病毒治疗或HIV病毒未抑制者更易诊断和住院;至少接种1剂天花/猴痘疫苗预防猴痘有效性为71%(调整RR 0.29,95%CI 0.14-0.47),CD4≥350或病毒抑制者达86%以上。

要点

  • 未抗逆转录病毒治疗或HIV病毒未抑制的HIV感染者更易诊断猴痘并住院。
  • 至少1剂天花/猴痘疫苗预防猴痘有效性71%(调整RR 0.29,95%CI 0.14-0.47)。
  • CD4≥350或HIV病毒抑制者疫苗有效性达86%以上。

核心结论

  • 未抗逆转录病毒治疗或HIV病毒未抑制的HIV感染者更可能诊断猴痘并住院。
  • 天花/猴痘疫苗有效性高,包括CD4计数低和HIV病毒血症者。

研究设计与样本

  • 纳入美国9个艾滋病研究中心网络站点2022年1月1日后有初级保健就诊的HIV感染者19777名。
  • 识别2022年6月1日至2023年5月31日诊断的猴痘,依据聚合酶链反应结果、诊断编码和/或tecovirimat领取。
  • 评估猴痘诊断、住院、tecovirimat治疗和疫苗接种的相对风险(RR)。

主要发现

  • 19777名HIV感染者中发生413例猴痘病例(均为出生时男性),发病率2.2例/100人年。
  • 年龄<40岁、地理区域、西班牙裔/拉丁裔族裔、未接受抗逆转录病毒治疗、可检测HIV病毒载量和近期细菌性性传播感染预测猴痘诊断。
  • CD4 200-349个细胞/mm3者住院可能性最高(调整RR 3.20;95%CI 1.44-7.09,对比CD4≥500),但接受tecovirimat治疗的可能性为CD4<200者的一半。
  • 至少1剂天花/猴痘疫苗预防猴痘有效性为71%(调整RR 0.29;95%CI 0.14-0.47),CD4≥350或HIV病毒抑制者达86%或更高。
  • 非西班牙裔黑人HIV感染者接种疫苗可能性低于其他种族/族裔身份者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Since its global reemergence in 2022, monkeypox (mpox) has demonstrated increased incidence and severity among people with human immunodeficiency virus (HIV [PWH]). Predictors of mpox diagnosis, vaccination, and outcomes among PWH are limited. METHODS: We included PWH with primary care visits after 1 January 2022 at 9 US sites participating in the Centers for AIDS Research Network of Integrated Clinic Systems Network. We identified mpox diagnosed between 1 June 2022 and 31 May 2023, through a combination of polymerase chain reaction result, diagnosis code, and/or tecovirimat receipt. We examined validated clinical diagnoses, laboratory results, vaccine data, and patient reported outcomes. We evaluated relative risks (RR) of mpox diagnosis, hospitalization, tecovirimat treatment, and vaccine receipt. FINDINGS: Among 19 777 PWH in care, 413 mpox cases (all male sex at birth) occurred (2.2 cases/100 person-years). Age <40 years, geographic region, Hispanic/Latine ethnicity, lack of antiretroviral therapy, detectable HIV viral load, and recent bacterial sexually transmitted infection predicted mpox diagnosis. PWH with CD4 200-349 cells/mm3 were most likely to be hospitalized (adjusted RR, 3.20; 95% confidence interval: 1.44-7.09) compared to CD4 ≥500, but half as likely as those with CD4 <200 to receive tecovirimat. Overall, smallpox/mpox vaccine effectiveness of ≥1 vaccine was 71% (adjusted RR, 0.29; 95% confidence interval: .14-.47) at preventing mpox, and 86% or better with CD4 ≥350 or HIV viral suppression. Non-Hispanic Black PWH were less likely to be vaccinated than other racial/ethnic identities. INTERPRETATION: PWH not on antiretroviral therapy or with unsuppressed HIV were more likely to be diagnosed with, and hospitalized for, mpox. Mpox/smallpox vaccine effectiveness was high, inclusive of those with low CD4 count and HIV viremia.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Montaño M, Shapiro AE, Whitney BM, et al. Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort. Clin Infect Dis. 2026. PMID: 39377755. doi:10.1093/cid/ciae464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。